Summary: An advantage of using LC-MS( W MS) for in vitro CYP inhibition screening is that it does not require extensive sample preparation and chromatographic separation. Attention must be paid, however, to ion suppression eŠects on analytes caused by the test compound as well as endogenous compounds. In this study, we have shown the ion suppression of 1?-hydroxymidazolam (analyte) and dextrorphan (IS) by erythromycin, as an example, which may cause over-or underestimation of CYP3A4 inhibition. To avoid this kind of eŠect, we proposed to use a stable isotope-labeled substrate and determine labeled metabolites by using unlabeled authentic compounds of each metabolite. We showed that CYP3A4 activity was determined with high accuracy and precision by using stable isotope-labeled midazolam even in the presence of an ion suppressor at high concentrations in the samples. This method is useful not only for the CYP inhibition screening but also for testing drug candidates to predict changes in metabolite formation by the possible co-administered drugs.
Introduction
In the early stages of drug development, enzyme inhibition screening is conducted to eliminate drug candidates possessing the risk of drug-drug interaction (DDI). Typically, the eŠect of a test compound to inhibit the formation of a metabolite from a probe substrate is evaluated. Concentrations of the metabolites formed from the probe compounds are determined by the LC-MS (or LC-MS W MS) method. LC-MS(W MS) is advantageous for its high selectivity that allows detection of the analyte without extensive sample preparation or separation on an analytical column.
We often experience cases, however, where the test compounds suppress ionization of the analyte (the metabolite of the probe compound) or the internal standard (IS) of the assay. Suppression of ionization of the analyte or IS leads to misjudgment of the test compound as an inhibitor or activator, respectively. The problem is that it is almost impossible to notice the occurrence of ion suppression in routine assays because LC-MS analysis in this kind of screening is usually carried out underˆxed conditions. Even if one suspects the suppression of ionization, it is not practical to optimize the conditions for each test compound.
The eŠect of ion suppression can be corrected by using the stable isotope of the analyte as an IS for LC-MS( W MS) assay. Walsky et al. 1) reported a validated method of CYP inhibition screening by using the stable isotope of each CYP probe metabolite as the IS, which enabled them to avoid the eŠect of ion-suppression. However, obtaining stable isotopes of the metabolite for each probe compound is not easy, because commercially available stable isotope-labeled probe metabolites for metabolizing enzymes are quite limited.
CYP3A4 is the most important CYP isozyme that accepts a great number of medicines as substrates. Inhibition of CYP3A4 may cause serious DDI. In the in vitro CYP3A4 study, a substrate-diŠerential response was reported. [2] [3] [4] ) and glucose-6-phosphate dehydrogenase (G6PDH) were purchased from Oriental Yeast (Tokyo). Potassium phosphate buŠer (K-Pi), 0.5 M, pH 7.4, 1 M magnesium chloride (MgCl2) and 0.5 M ethylene diamine tetraacetic acid (EDTA), pH 8.0, were obtained from Nakalai Tesque (Kyoto, Japan), Ambion (Austin, TX, USA) and Gibco (Gaithersburg, MD, USA), respectively. Methanol, acetonitrile, and dimethylsulfoxide (DMSO) were purchased from Kanto Chemical (Tokyo).
Microsomal incubations: The incubation mixture contained aˆnal concentration of 0.05 mg protein W mL HLM, 100 mM K-Pi, 0.05 mM EDTA, NADPH generating system (5 mM G6P, 1 unit W mL G6PDH, 5 mM MgCl2, 0.5 mM NADP ＋ ), a substrate and a test compound (inhibitor). Theˆnal volume of the incubation mixture was 200 mL. The incubation mixture was pre-warmed at 379 C for 5 min before the start of the reaction. The enzyme reaction was started by adding the NADPH generating system. After incubation at 379 C for 10 min, the reaction was terminated by adding 600 mL of methanol containing the IS to 200 mL of the incubation mixture. Samples were centrifuged at 20000 g for 10 min at 49 C and 10 mL of the supernatant was injected into the LC-MS W MS. Frankfurt, Germany) . The column temperature was set at 409 C. The mobile phase consisted of 0.1z formic acid in water (A) and 0.1z formic acid in acetonitrile (B). The initial condition was set at 5z of B, which was maintained for 0.5 min. Then B (z) was increased linearly to 35z from 0.5 to 1 min and maintained to 3.5 min, further increased to 95z and maintained to 5.5 min, and then brought back to the initial concentration linearly from 5.5 to 5.8 min. The ‰ow rate was 0.6 mL W min from 0 to 4.4 min and increased to 2 mL W min in 0.3 min. MS was performed using a Quattro Ultima triple-stage quadropole mass spectrometer. N2 gas was used for both the cone and desolvation gases. triplicate incubations) to the following equation using the same software, where y is z of control, x is concentration of the inhibitor, and S is a slope factor. y＝ 100
LC-MS
1＋ Ø x IC50 » S
Results
EŠect of ion-suppression on the LC-MS W MS analysis: Figure 1 shows the eŠect of erythromycin on the peak area of 1?-OH-MDZ and DXO (IS), and on the peak area ratio (1?-OH-MDZ W DXO). All of the samples contained the same concentrations of 1?-OH-MDZ and DXO. However, as the concentration of erythromycin increased, the peak areas of both 1?-OH-MDZ and DXO decreased, but to diŠerent extents, and the peak area ratio (1?-OH-MDZ W DXO) decreased. -1 i.e. the concentration (peak area ratio W mL) corrected for incubation time (min) and microsomal protein concentration (mg protein W mL).
Inhibition study with ketoconazole: Figure 5 shows the inhibition of 1?-hydroxylation of [ 13 C4, 15 N]-MDZ by ketoconazole, a positive control of CYP3A4 inhibitor, which was assayed by using 1?-OH-MDZ as the IS. The IC50 of ketoconazole was calculated to be 14.4 nM.
Discussion
To select drug candidates that will be free from the risk of DDI after launch, pharmaceutical companies have introduced CYP inhibition screening, whereby the eŠect of test compounds on the metabolism of a probe substrate is determined. In early screening, a highthroughput screening system using recombinant human CYP isozymes and ‰uorescent substrates [4] [5] [6] is common. However, we regard this system as being less predictive of in vivo DDI compared with the screening system using human microsomes and probe compounds that are administered to humans. This is because the inhibition by metabolites of the test compounds formed by the other isozymes is ignored in the recombinant CYP system, and inhibition of CYP enzymes may diŠer depending on the substrate used as is often the case with CYP3A4. [2] [3] [4] In the human microsome system, metabolites of probe compounds are generally determined by the LC-MS W MS method. The high selectivity and high sensitivity of LC-MS W MS are believed to be advantageous for high throughput screening since samples can be injected into the LC-MS W MS without extensive extraction and puriˆcation. In addition, the HPLC condition does not aim to separate the analytes on the analytical column, and the run time is usually only a few minutes. However, a situation where the test compound suppresses ionization of the analyte may occur. As shown in Fig. 1 , when ionization of the analyte and IS are suppressed and the extent of suppression is greater for the analyte, it appears that the concentration of 1?-OH-MDZ decreases as the erythromycin concentration increases. If this kind of concentration-dependent ion suppression happens in the enzyme inhibition assay, the test compound is misjudged as a potent inhibitor. If, however, the test compound suppresses the ionization of IS more extensively, the compound is misjudged as an inducer.
In early screenings, it is not practical to optimize the analytical condition for each compound. Thus, the addition of a stable isotope of the metabolite as an IS, as reported by Walsky and Obach, 1) is a common way to correct the eŠect of ion suppression. Here, we have shown that using a stable isotope-labeled probe compound as a substrate and determining a labeled metabolite by using an unlabeled metabolite as an IS is another way to overcome this problem. We developed the CYP3A4 inhibition screening using [ 13 C 4 , 15 N]-MDZ as a substrate, as an example. CYP3A4 is one of the most important CYP isozymes involved in DDI, and MDZ is recommended by the FDA to be used as a probe for CYP3A4 in both in vitro and in vivo studies.
First, we validated the assay of 1?-OH-[ 13 C 4 , 15 N]-MDZ in the incubation sample. As shown in Fig. 2 We invented the method of using stable isotopelabeled probe compounds when stable isotope-labeled metabolites of typical CYP substrates used in the inhibition assay were not available. Although stable isotopelabeled metabolites of some CYP substrates have been put on market recently, this strategy is useful for drug development, because the numbers of available stable isotope-labeled metabolites are still quite limited. Also, if one intends to evaluate DDI between a drug candidate and possible co-administered drugs, it would be beneˆ-cial to use the stable isotope-labeled drug as a substrate and evaluate the eŠect of possible co-administered drugs on the formation of each metabolite. Usually, the stable isotope of a drug candidate is synthesized relatively early in the drug development process for use as an IS for LC-MS( W MS) assays in pharmacokinetic and toxicokinetic studies. Presumed metabolites are also synthesized by this time.
Finally, we refer to the cost of using stable isotopes. N]-MDZ cost accounts for only a small part in the whole assay.
Conclusion
We warned that concentration-dependent ion suppression in the LC-MS W MS assay is a source of misjudgment in enzyme inhibition screening using human liver microsomes. To avoid this risk in routine enzyme inhibition assays, we proposed to use a stable isotope-labeled substrate as a substrate and to monitor the stable isotope-labeled metabolite by using unlabeled metabolite as an IS. Example of CYP3A4 assay using commercially available [ 13 C4, 15 N]-MDZ was shown. The activity was determined with high accuracy and precision in the presence of high concentrations of an ion-suppressing compound. Kinetic parameters for 1?-hydroxylation of [ 13 C4, 15 N]-MDZ were comparable to those of unlabeled MDZ. These observations indicate that using an stable isotope-labeled substrate is a useful means to avoid ion suppression in enzyme inhibition studies.
